Novartis AG【NVS】株式ニュース

個人投資家向けのプロ仕様のツール。

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program PR...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer PR...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

October 3, 2024 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: Pharmaceutical companies are demonstrating innovation by...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14

LEXINGTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a...

Lindy Biosciences stringe un accordo di licenza e collaborazione con Novartis per la somministrazione innovativa di farmaci multitarget

Novartis si assicura i diritti esclusivi globali alla tecnologia di microglassification di Lindy Biosciences in diversi target biologici La...

Lindy Biosciences conclut un accord de licence et de collaboration avec Novartis pour l’innovation en matière d’administration de médicaments à cibles multiples

Novartis obtient les droits mondiaux exclusifs sur la technologie de microglassification de Lindy Biosciences pour de multiples cibles...

Lindy Biosciences schließt Lizenzierungs- und Kooperationsvereinbarung mit Novartis für Wirkstoffabgabeinnovation für mehrere Zielmoleküle ab

Novartis sichert sich die weltweiten Exklusivrechte an der Mikroverglasungstechnologie von Lindy Biosciences für mehrere biologische...

https://www.sciencetimes.com/articles/50071/20240508/anavex-life-sciences-alzheimers-treatment-brings-hope-to-millions.htm

👍️0

da_stock_analyst 9月前

Radiopharma stocks higher as sector welcomes the latest M&A deal https://seekingalpha.com/news/4099035-novartis-mariana-oncology-deal-drives-radiopharma ..Shares of radiopharma companies spiked as investors welcomed the latest M&A deal to hit the sector. $NVS $CATX $CLRB $CASI $LNTH and ATNM. for more info click here https://shorturl.at/hoU47

have you seen yesterday that enzolytics pharm announced that they now have a CURE for hiv/aids called clone3.?

👍️0

ernie44 1年前

its a home run ---or is it just the runs

https://apis.mail.yahoo.com/ws/v3/mailboxes/@.id==VjN-cV7LhC8rx0EcG5-z9RhWgRsQvGZwTs2qwUxoYR9UStj84lOVi7ZIeMO8HFiplsA65ZbE_cF9gB9A2TSm5APqCg/messages/@.id==AA43g3BH-2gCZMlFEQgiCNhLPmU/content/parts/@.id==2/thumbnail?appid=YMailNorrin&downloadWhenThumbnailFails=true&pid=2

👍️0

awesomed007 2年前

https://www.prnewswire.com/news-releases/dtx-pharma-announces-acquisition-by-novartis-301877974.html. I have cmt. Getting closer to 1st fda approved treatment, hopeful!!!

👍️0

subslover 3年前

Former Head of Novartis Respiratory and Allergy Medicine to Advise Clinical Stage Stem Cell Company on COVID-19 and COPD Programs
https://www.otcmarkets.com/stock/TSOI/news/story?e&id=2224788

👍️0

FACT-MASTER 3年前

https://www.novartis.com/news/media-releases/new-novartis-data-demonstrate-only-kisqali-offers-more-life-first-line-setting-postmenopausal-hrher2-advanced-breast-cancer-patients

👍️0

FACT-MASTER 3年前

https://www.novartis.com/news/media-releases/novartis-kymriah-receives-ec-approval-first-car-t-cell-therapy-adults-relapsed-or-refractory-follicular-lymphoma

👍️0

FACT-MASTER 3年前

Novartis also has a collaboration agreement with TScan Therapeutics for development of TCR-T cancer technology, one of the latest and promising therapeutics that could accompany CAR-T.

https://ir.tscan.com/news-releases/news-release-details/tscan-announces-collaboration-novartis-discovery-and-development

TScan entering clinical Phase 1 in 1H 2022.

👍️0

DewDiligence 3年前

FDA approves NVS’ Pluvicto*, a radioligand for CRPC:

https://www.globenewswire.com/news-release/2022/03/23/2408996/0/en/Novartis-PluvictoTM-approved-by-FDA-as-first-targeted-radioligand-therapy-for-treatment-of-progressive-PSMA-positive-metastatic-castration-resistant-prostate-cancer.html

NVS obtained this agent from the ECYT buyout in 2018 (#msg-144295734).

*f/k/a 177Lu-PSMA-617.

👍️0

DewDiligence 3年前

FDA approves NVS’ Leqvio—(inclisiran)—for lowering LDL-C:

https://www.prnewswire.com/news-releases/fda-approves-novartis-leqvio-inclisiran-first-in-class-sirna-to-lower-cholesterol-and-keep-it-low-with-two-doses-a-year-301450125.html

NVS initially received a CRL from the FDA in late 2020 due to the FDA’s inability to conduct an inspection of the Leqvio’s manufacturing site in Italy (#msg-160327185).

Leqvio is a siRNA dosed semiannually (except for the 3-month interval between the first two doses). NVS picked up this drug when it acquired MDCO in Nov 2019 (#msg-152458295).

ALNY, which will get a 10-20% royalty on global sales, discovered Inclisiran and out-licensed it to MDCO in 2013 (#msg-84151150); with the benefit of hindsight we can say that MDCO clearly got the better of ALNY in this deal.

Leqvio was approved in the EI in late 2020 (https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-leqvio-inclisiran-first-class-sirna-lower-cholesterol-two-doses-year ).

👍️0

DewDiligence 3年前

NVS plans $15B share buybacks through 2023—exhausting ~70% of the proceeds from the recent sale of Roche shares:

https://finance.yahoo.com/news/novartis-initiates-usd-15-billion-060000184.html

This might be one reason XBI was down today.

👍️0

ht1 4年前

Novartis should invest in mRNA medicine and pair up with companies like Regen Biopharma to speed up this process. Perhaps an outright purchase of this start up company. This will ensure competing with likes of Pfizer and Moderna.

👍️0

DewDiligence 4年前

FDA_advisory_panel_endorses Entresto for_heart_failure_in_12-1_vote:

https://www.prnewswire.com/news-releases/novartis-announces-positive-fda-advisory-committee-recommendation-for-use-of-entresto-to-treat-patients-with-hfpef-301193607.html

👍️0

dshade 4年前

good news today - Novartis Says Asciminib Showed Superior MMR Rate to Bosulif in Leukemia Trial
December 08 2020 - 11:00AM
Dow Jones News

By Michael Dabaie

Novartis AG said asciminib showed superior major molecular response rate to Bosulif in a chronic myeloid leukemia trial.

The company said results from a Phase III study demonstrate that at 24 weeks, asciminib nearly doubled the major molecular response rate compared with Bosulif in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibitor therapies.

The data were presented at a late-breaking abstracts session during the 62nd American Society of Hematology Annual Meeting & Exposition, Novartis said.

In the trial, 233 patients were randomized to receive asciminib 40 mg twice daily or Bosulif 500 mg once a day.

Novartis said the U.S. Food and Drug Administration granted Fast Track designation for asciminib. The company said it plans submission to U.S. and EU health authorities in the first half of 2021.

CHMP approves NVS’ Leqvio (inclisiran) for hypercholesterolemia or mixed dyslipidemia:

https://www.globenewswire.com/news-release/2020/10/16/2109800/0/en/Novartis-receives-positive-CHMP-opinion-for-Leqvio-inclisiran-a-potential-first-in-class-siRNA-for-the-treatment-of-high-cholesterol.html

Rubber-stamping by the European Commission will follow in 2-3 months.

👍️0

DewDiligence 4年前

NVS/GMAB—FDA approves Kesimpta—(subcutaneous ofatumumab)—for MS:

https://finance.yahoo.com/news/u-fda-approves-kesimpta-ofatumumab-173300452.html
https://t.co/9AOLIf7Qln?amp=1

NVS acquired the commercial rights to ofatumumab from GSK, and NVS will pay GSK a tiered royalty up to 12% on worldwide sales of Kesimpta (#msg-116391951).

Ofatumumab, administered via IV, was FDA-approved for CLL under the brand name, Arzerra in 2009 (#msg-42935958).

👍️0

DewDiligence 5年前

Ofatumumab PFUFA delayed 3mo—>Sep 2020 for MS indication:

https://www.globenewswire.com/news-release/2020/06/02/2042559/0/en/Novartis-provides-update-on-FDA-review-of-ofatumumab-a-self-administered-targeted-B-cell-therapy-for-patients-with-relapsing-multiple-sclerosis.html

The PR does not cite a reason for the delay.

NVS acquired Ofatumumab’s commercial rights in MS from GSK in a 2015 transaction involving a $500M up-front payment by NVS (#msg-116391951).

👍️0

fung_derf 5年前

What am I missing here? Why is no one talking about Novartis for their hydroxychloroquine?

👍️0

DewDiligence 5年前

NVS concedes Beovu has new safety issue:

https://www.brolucizumab.info/ Novartis has now completed its review of these post-marketing safety case reports… Based on internal and SRC assessment, it was concluded that there is a confirmed safety signal of rare adverse events of “retinal vasculitis and/or retinal vascular occlusion with or without presence of intraocular inflammation that may result in severe vision loss.”

Based on this review, Novartis has initiated a safety information update to Beovu prescribing information worldwide. Currently approved prescribing information includes intraocular inflammations, visual acuity decrease (including blindness) and retinal artery occlusion as separate terms. We will work with regulatory authorities to finalize the prescribing information update.

In addition, we are working with our data monitoring committees and informing investigators of ongoing clinical trials. Novartis-sponsored studies will be amended so that protocols, Informed Consent Forms and Investigator Brochures reflect this new safety information. Investigators are also being informed to re-consent patients.

It won't have any effect at all on the share price. It's a goodwill gesture and it's the right thing to do morally.

👍️0

Maddog 112 5年前

How much will this affect the stock price 160 mil pills at 4$ is a lot of money

👍️0

DewDiligence 5年前

Yes—that was announced on Friday: #msg-154462215.

👍️0

Maddog 112 5年前

Is it true NVS to supply 160 mil chloroquine pills to America to help fight corona virus

👍️0

DewDiligence 5年前

More on the same story (Beovu safety):

https://endpts.com/novartis-plans-to-wrestle-eylea-market-share-take-a-hit-as-beovu-is-linked-to-safety-concerns/

👍️0

DewDiligence 5年前

Acceptance of a BLA/NDA application for review doesn’t generally move the needle for a company as large as NVS unless the FDA grants a priority review when investors expected a standard review, which wasn’t the case here.

👍️0

Ecomike 5年前

And so this got ignored.

https://ih.advfn.com/stock-market/NYSE/novartis-NVS/stock-news/81828953/novartis-fda-ema-accept-filings-for-ofatumumab-i?xref=ff_sidebar_quote

👍️0

DewDiligence 5年前

The cause is a safety update re Beovu (the recently approved drug for AMD):

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153989588

https://www.statnews.com/2020/02/24/safety-concerns-regarding-novartiss-new-eye-drug-boost-regeneron-stock/

👍️0

Ecomike 5年前

5.5% drop on a biotech drug firm like NVS 8 days before the dividend date looks way over done to me with Biotechs in favor and nothing but Good news today and recently on NVS.

Panic selling seems way over done. But then again panics are like that.

You see any bad news at all on NVS I missed?

👍️0

DewDiligence 5年前

NVS 12/5/19 R&D Day slides:

https://www.novartis.com/sites/www.novartis.com/files/2019-12-05-novartis-r-d-day-investor-presentation.pdf

👍️0

DewDiligence 5年前

NVS PR in conjunction with R&D Day investor webcast:

https://www.globenewswire.com/news-release/2019/12/05/1956569/0/en/Novartis-expects-to-sustain-long-term-growth-with-a-robust-pipeline-of-25-potential-blockbusters-highlighted-at-R-D-Day.html

👍️0

elotto777 5年前

These shares are a BUY - Up and Away is how we would describe this company
READ REPORT HERE https://pennystocks.news/biotech-mega-merger-novartis-buys-medicines-co-9-7-billion-deal/

👍️0

DewDiligence 5年前

NVS acquires MDCO for $85/sh cash—a 64% premium to MDCO’s closing price on 11/15/19, the day before serious buyout rumors began circulating:

https://www.globenewswire.com/news-release/2019/11/24/1951667/0/en/Novartis-to-acquire-The-Medicines-Company-for-USD-9-7-bn-adding-inclisiran-a-potentially-transformational-investigational-cholesterol-lowering-therapy-to-address-leading-global-cau.html

https://www.novartis.com/sites/www.novartis.com/files/novartis-mdco-acquisition.pdf (CC slides)

The nominal deal value is $9.7B (on a fully-diluted basis). There is no CVR.

👍️0

DewDiligence 5年前

CHMP approves NVS’ Mayzent for SPMS:

https://www.globenewswire.com/news-release/2019/11/15/1947899/0/en/Novartis-receives-positive-CHMP-opinion-for-Mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-SPMS.html

👍️0

whytestocks 5年前

News: $NVS ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG - NVS

NEW YORK, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Novartis AG (NYSE: NVS) resulting from allegations that Novartis may have issued materially misleading business in...

Read the whole news NVS - ROSEN, A LEADING GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG - NVS

👍️0

DewDiligence 5年前

FDA approves NVS’ Beovu—(a/k/a brolucizumab/RTH258) for wet AMD—3mo dosing interval after the loading phase:

https://www.globenewswire.com/news-release/2019/10/08/1926199/0/en/Novartis-receives-FDA-approval-for-Beovu-offering-wet-AMD-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept.html

US list price will be $1,850 per vial—inline with main competitor Eylea—according to Vantage (https://www.globenewswire.com/news-release/2019/10/08/1926199/0/en/Novartis-receives-FDA-approval-for-Beovu-offering-wet-AMD-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept.html ).

👍️0

DewDiligence 5年前

Here's the cause of today's sell-off:

https://www.wsj.com/articles/fda-says-data-manipulation-occurred-in-trials-of-world-s-priciest-drug-11565116881

👍️0

Ecomike 5年前

Any clue what too the air out this one this afternoon?

I see no news yet to justify the swan dive mid day today.

👍️0

Ecomike 6年前

I would love to hear more about that whole story?

👍️0

biopharm 6年前

Novartis been researching PS Phosphatidylserine targeting ?

Drug: MBG453
MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).
...
...

Dew, what do you think of the rumors swirling around PS Targeting drugs? Novartis has been swirling all around PS Targeting ever since they brought on Glen Dranoff from Dana Farber ...

Now with Dana Farber Gordon Freeman and Clive Wood enhancing patents that they collaborated on ....patents surrounding PS Targeting are key

👍️0

PennyStock Alert 6年前

Green after hours trading

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Novartis AG (NVS)

個人投資家向けのプロ仕様のツール。

NVS ニュース

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14

Lindy Biosciences stringe un accordo di licenza e collaborazione con Novartis per la somministrazione innovativa di farmaci multitarget

Lindy Biosciences conclut un accord de licence et de collaboration avec Novartis pour l’innovation en matière d’administration de médicaments à cibles multiples

Lindy Biosciences schließt Lizenzierungs- und Kooperationsvereinbarung mit Novartis für Wirkstoffabgabeinnovation für mehrere Zielmoleküle ab

NVS Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Novartis AG (NVS) ニュース

Novartis AG (NVS)

個人投資家向けのプロ仕様のツール。

NVS ニュース

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14

Lindy Biosciences stringe un accordo di licenza e collaborazione con Novartis per la somministrazione innovativa di farmaci multitarget

Lindy Biosciences conclut un accord de licence et de collaboration avec Novartis pour l’innovation en matière d’administration de médicaments à cibles multiples

Lindy Biosciences schließt Lizenzierungs- und Kooperationsvereinbarung mit Novartis für Wirkstoffabgabeinnovation für mehrere Zielmoleküle ab

NVS Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手